Healthcare Services

Choroidal Neovascularization Market: Key Developments Driving Growth

April 20, 2026April 20, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Growth In Market Value Is Expected For The Choroidal Neovascularization Market Between 2026 And 2030?

The market size for choroidal neovascularization has experienced substantial expansion in recent years. This market is anticipated to expand from $4.18 billion in 2025 to $4.5 billion in 2026, progressing at a compound annual growth rate (CAGR) of 7.7%. The historical growth can be linked to several factors, including the increasing occurrence of age-related macular degeneration, a rise in diabetic eye disease cases, the proliferation of ophthalmology clinics, the accessibility of anti-angiogenic drugs, and improvements in retinal diagnostic capabilities.

The choroidal neovascularization market is projected to experience robust expansion over the coming years. This market is anticipated to reach a valuation of $5.99 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.4%. Factors contributing to this growth during the projected period include an expanding aging demographic, heightened emphasis on prompt ophthalmic interventions, the broadening of combination therapy methods, increasing investments dedicated to retinal disease research, and a greater uptake of personalized treatment protocols. Key trends shaping the market within the forecast timeframe encompass the wider acceptance of anti-VEGF therapies, the increasing application of treat-and-extend regimens, a rising need for early CNV diagnosis, the proliferation of sophisticated retinal imaging techniques, and an intensified focus on therapies aimed at preserving vision.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/choroidal-neovascularization-global-market-report

Which Primary Drivers Are Impacting The Choroidal Neovascularization Market Growth?

The increasing occurrence of age-related macular degeneration (AMD) is anticipated to drive the expansion of the choroidal neovascularization (CNV) market in the future. AMD is an ocular condition that progressively impairs the macula, resulting in the loss of central vision, predominantly among older individuals. This surge in AMD cases stems from an aging demographic, extended life spans, evolving lifestyles, genetic predispositions, and heightened environmental risk exposure. CNV plays a role in patients with AMD by fostering the emergence of wet AMD, a condition characterized by the formation of aberrant blood vessels under the retina, causing visual decline. Managing CNV and retarding AMD progression often necessitates advanced therapies like anti-VEGF treatment to help maintain central vision for those afflicted. For instance, the UHN Foundation, Canada-Based official fundraising arm, stated that by 2025, AMD will be the leading cause of considerable, permanent vision impairment in people aged over 50. Presently impacting more than 200 million individuals worldwide, this figure is predicted to climb to 288 million by 2040. Consequently, the expanding incidence of age-related macular degeneration is fueling the growth of the choroidal neovascularization market.

Which Segment Types Are Examined In The Choroidal Neovascularization Market Segment Study?

The choroidal neovascularization market covered in this report is segmented –

1) By Treatment Type: Anti-Angiogenic Therapy, Laser Photocoagulation, Photodynamic Therapy, Verteporfin Sodium, Ranibizumab, Bevacizumab, Aflibercept, Pegaptanib Sodium

2) By Indication: Age-Related Macular Degeneration (AMD), Diabetic Macular Edema (DME), Central Serous Chorioretinopathy (CSC), Polypoidal Choroidal Vasculopathy (PCV), Myopic Macular Degeneration (MMD), Other Indications

3) By Route Of Administration: Intravitreal, Subconjunctival, Periocular, Oral

4) By End User: Hospitals, Ophthalmology Clinics, Ambulatory Surgical Centers, Research Centers

Subsegments:

1) By Anti-Angiogenic Therapy (Anti-VEGF Therapy): Ranibizumab, Bevacizumab, Aflibercept, Pegaptanib Sodium

2) By Laser Photocoagulation: Thermal Laser Photocoagulation, MicroPulse Laser Therapy

3) By Photodynamic Therapy (PDT): Standard PDT, Low-Fluence PDT, Half-Dose PDT

4) By Verteporfin Sodium: Intravenous Administration, Combination Therapy With Anti-VEGF

5) By Ranibizumab: Monthly Dosing, As-Needed Dosing, Treat-and-Extend Regimen

6) By Bevacizumab: Off-Label Use, Compounded Intravitreal Injections

7) By Aflibercept: Fixed-Dosing Regimen, Treat-and-Extend Regimen

8) By Pegaptanib Sodium: Monotherapy, Combination Therapy

Which Trends Are Shaping Growth In The Choroidal Neovascularization Market?

Leading companies in the choroidal neovascularization market are prioritizing the development of innovative therapies, such as photodynamic therapy, to provide eye care professionals with precise, efficient treatment solutions that improve patient outcomes and enhance treatment delivery. Photodynamic therapy (PDT) functions as a medical procedure employing a photosensitizing agent activated by light to specifically target and destroy abnormal or cancerous cells. For instance, in February 2023, Bausch & Lomb, a Canada-based healthcare company, alongside Modulight, a Finland-based biomedical company, announced the ML6710i photodynamic laser, which received approval from the Food and Drug Administration, a US-based federal agency. This therapy is approved for use with Bausch + Lomb’s VISUDYNE therapy, which is designed to treat choroidal neovascularization caused by age-related macular degeneration (AMD). This modern, mobile ophthalmic laser offers a targeted approach for treating abnormal blood vessels in the eye, thereby helping to prevent further disease progression and preserve vision.

Which Players Are Part Of The Competitive Landscape Of The Choroidal Neovascularization Market?

Major companies operating in the choroidal neovascularization market are Roche Holding AG, Regeneron Pharmaceuticals Incorporated, Bayer Aktiengesellschaft, Novartis AG, Apellis Pharmaceuticals Incorporated, Kodiak Sciences Incorporated, Adverum Biotechnologies Incorporated, Clearside Biomedical Incorporated, Graybug Vision Incorporated, Outlook Therapeutics Incorporated, Oxurion NV, 4D Molecular Therapeutics Incorporated, Opthea Limited, Eyepoint Pharmaceuticals Incorporated, Ocular Therapeutix Incorporated, OcuTerra Therapeutics Incorporated, Ocuphire Pharma Incorporated, Kubota Vision Incorporated, Amgen Incorporated, Coherus BioSciences Incorporated, Formycon AG, Alimera Sciences Incorporated, Neurotech Pharmaceuticals Incorporated, Alkeus Pharmaceuticals Incorporated, Aerie Pharmaceuticals Incorporated, Acucela Incorporated

Get The Full Choroidal Neovascularization Market Report:

https://www.thebusinessresearchcompany.com/report/choroidal-neovascularization-global-market-report

Which Geographic Region Dominates The Choroidal Neovascularization Market?

North America was the largest region in the choroidal neovascularization market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the choroidal neovascularization market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Choroidal Neovascularization Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/choroidal-neovascularization-global-market-report

Browse Through More Reports Similar to the Global Choroidal Neovascularization Market 2026, By The Business Research Company

Ocular Hypertension Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/ocular-hypertension-treatment-global-market-report

Intravascular Ultrasound Market Report 2026

https://www.thebusinessresearchcompany.com/report/intravascular-ultrasound-global-market-report

Vascular Imaging Market Report 2026

https://www.thebusinessresearchcompany.com/report/vascular-imaging-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795